News Search Results
Aug 08, 2025, 08:03 ET HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Receipt of Final Clearance to Proceed to Closing of Dura Medical Acquisition from Florida's Agency for Health Care Administration (AHCA)
Florida Dura delivers a full range of precision psychiatry services for severe depression, PTSD and related CNS disorders, including Ketamine therapy and Transcranial Magnetic Stimulation (TMS), to veteran and civilian patients Acquisition expected
More news about: NRx Pharmaceuticals, Inc.
Aug 07, 2025, 09:00 ET Cipla Expands Fall River Operations in USA, Announces Upcoming Hiring for Various Roles
North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms
More news about: Cipla USA Inc.
Aug 07, 2025, 07:00 ET Firefly Fiber Broadband Selects Corero Network Security for Scalable DDoS Protection Across Expanding Infrastructure
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a recognized leader in DDoS protection and champion of adaptive, real-time service availability, today announced a new customer win
More news about: Corero Network Security
Aug 06, 2025, 10:45 ET Biomarkers Market to Grow at a CAGR of 12.3% from 2025 to 2032 | SkyQuest Technology Consulting
Comprehensive Test, which covers over 500 genes and supports precision oncology applications. Similarly, Alamar Biosciences launched the NULISAseq™ CNS Disease Panel 120 in March 2024, targeting early detection of neurodegenerative diseases using ultra-sensitive protein
More news about: SkyQuest Technology
Aug 06, 2025, 10:01 ET Pharmaceutical Suppositories Market is expected to generate a revenue of USD 2.74 Billion by 2032, Globally, at 5.91% CAGR: Verified Market Research®
Size By Type (Early Phase Development Services, Clinical Trial Services, Laboratory Services, Consulting Services), By Therapeutic Area (Oncology, CNS Disorders, Cardiovascular Diseases, Infectious Diseases, Metabolic Disorders), By End User (Pharmaceutical & Biopharmaceutical Companies, Medical
More news about: Verified Market Research
Aug 06, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers - ANRO
pro-neurogenesis/neuroplasticity mechanism of action" and has stated that the Company "believe[s] binds a receptor not targeted by other [central nervous system ("CNS")] therapeutics, which would make it first-in-class if approved." On January 12, 2024, Alto filed a registration
More news about: Pomerantz LLP
Aug 06, 2025, 08:05 ET Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets
unmet medical needs using its patented iSPERSE™ technology. The Company's proprietary product pipeline includes treatments for central nervous system ("CNS") disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease ("COPD") and allergic bronchopulmonary aspergillosis
More news about: Pulmatrix Inc.
Aug 06, 2025, 07:02 ET The U.S. FDA Granted Fast Track Designation to Dizal's Birelentinib for Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
growth of B-NHLs in cell lines and in animal models. In clinical studies, birelentinib exhibits favorable PK properties, good central nervous system (CNS) permeability, complete blockade of BCR signaling, and encouraging anti-tumor efficacy with good safety and tolerability in patients with B-NHL.
More news about: Dizal Pharmaceutical
Aug 05, 2025, 16:01 ET Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update
its opt-in right related to the development and commercialization of ocadusertib (previously R552) for the treatment of non-central nervous system (CNS) diseases. As a result of the notification, Rigel recognized $40.0 million in non-cash revenue resulting from the release
More news about: Rigel Pharmaceuticals, Inc.
Aug 05, 2025, 08:00 ET Curis Provides Second Quarter 2025 Business Update
Analysis of genetic mutation profile and CNS pharmacokinetics in relapsed/refractory primary CNS lymphoma patients responding to novel emavusertib (IRAK4i) and BTKi combination.Continued to enroll relapsed/refractory
More news about: Curis, Inc.
Aug 03, 2025, 08:25 ET ANRO Investors Have the Opportunity to Lead the Alto Neuroscience Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
$17 from $33 and stated that ALTO-100's data raises questions around the Company's overall biomarker approach to CNS disorders and psychiatry. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class
More news about: Faruqi & Faruqi, LLP
Jul 31, 2025, 16:19 ET Cohen & Steers, Inc. Declares Quarterly Dividend
July 31, 2025 /PRNewswire/ -- The Board of Directors of Cohen & Steers, Inc. (NYSE: CNS) declared a cash dividend for the third quarter of 2025 in the amount of $0.62 per share of common stock payable on
More news about: Cohen & Steers, Inc.
Jul 31, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers - ANRO
a pro-neurogenesis/neuroplasticity mechanism of action" and has stated that the Company "believe[s] binds a receptor not targeted by other [central nervous system ("CNS")] therapeutics, which would make it first-in-class if approved." On January 12, 2024, Alto filed a registration
More news about: Pomerantz LLP
Jul 31, 2025, 07:00 ET Corero Network Security Partners with Beyond Technology MEA to Expand DDoS Protection in Pakistan
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the distributed denial of service (DDoS) protection specialists, announced a strategic partnership with
More news about: Corero Network Security
Jul 30, 2025, 17:55 ET Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
Jul 30, 2025, 17:51 ET Cohen & Steers REIT and Preferred and Income Fund, Inc. (RNP) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.com/Symbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
Jul 30, 2025, 17:48 ET Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
Jul 30, 2025, 17:44 ET Cohen & Steers Total Return Realty Fund, Inc. (RFI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.com/Symbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
Jul 30, 2025, 17:43 ET Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
Jul 30, 2025, 10:10 ET EuMentis Therapeutics Receives U.S. FDA Clearance of IND Application for EM-221, a Novel PDE10A Inhibitor for Schizophrenia
advancing novel treatments for schizophrenia and other central nervous system (CNS) conditions. EuMentis is committed to leading innovation in the neuropsychiatric disease field by advancing programs that target selective CNS circuits in the brain with clinically validated mechanisms of action. This approach
More news about: EuMentis Therapeutics, Inc.
Jul 30, 2025, 09:46 ET Alamar Biosciences spolupracuje s Německým centrem pro neurodegenerativní onemocnění (DZNE) na průlomovém proteomickém profilování v kohortě Studie Porýní
života. Nasazení panelu NULISAseq CNS Disease Panel 120 od společnosti Alamar výzkumníkům umožní stanovovat hladiny stovek proteinů s významem pro fungování mozku z minimálního objemu krve s výjimečnou citlivostí a specificitou. Pozoruhodná je zejména schopnost panelu CNS rozlišit fosforylovaný tau protein
More news about: Alamar Biosciences, Inc.
Jul 30, 2025, 09:27 ET Alamar BiosciencesとGerman Center for Neurodegenerative Diseases（DZNE）、ラインラント研究（Rhineland Study）コホートにおける画期的なプロテオミクス・プロファイリング研究で提携
NULISAseq™ CNS Disease Panel 120とInflammation Panel 250で、23,000件の縦断的検体におけるバイオマーカー発見を推進 カリフォルニア州フリーモント、2025年7月30日 /PRNewswire/ -- 精密プロテオミクス技術を活用し、疾患の早期発見を可能にするAlamar Biosciencesは本日、German Center for Neurodegenerative Diseases（DZNE）との戦略的提携を発表しました。この提携により、同社の超高感度NULISAseq™
More news about: Alamar Biosciences, Inc.
Jul 30, 2025, 09:01 ET Alamar Biosciences и Немецкий центр нейродегенеративных заболеваний (DZNE) совместно проводят знаковое исследование по протеотомному профилированию в когортном исследовании Rhineland Study
протяжении всей жизни. Используя панель NULISAseq CNS Disease Panel 120 от Alamar, исследователи смогут определять сотни белков, связанных с работой мозга, в минимальных объемах крови с исключительной чувствительностью и специфичностью. Так, способность панели CNS отличать фосфорилированный тау-белок из тканей
More news about: Alamar Biosciences, Inc.
Jul 30, 2025, 08:57 ET Alamar Biosciences dan German Center for Neurodegenerative Diseases (DZNE) bermitra untuk penelitian Landmark Proteomic Profiling dalam Kelompok Rhineland Study
sepanjang rentang kehidupan. Dengan menggunakan NULISAseq CNS Disease Panel 120 Alamar, peneliti akan dapat mengukur ratusan protein terkait otak dari volume darah yang minimal dengan sensitivitas dan kekhususan yang luar biasa. Khususnya kemampuan panel CNS dalam membedakan antara tau terfosforilasi yang berasal
More news about: Alamar Biosciences, Inc.
Jul 29, 2025, 22:09 ET Alamar Biosciences et le Centre allemand pour les maladies neurodégénératives (DZNE) s'associent pour une étude historique de profilage protéomique dans la cohorte d'étude rhénane
utilisant le NULISAseq CNS Disease Panel 120 d'Alamar, les chercheurs seront capables de mesurer des centaines de protéines liées au cerveau à partir de volumes sanguins minimes, avec une sensibilité et une spécificité exceptionnelles. En particulier, la capacité du panel CNS à distinguer la protéine
More news about: Alamar Biosciences, Inc.